We are live on ! Find out more
PA

Perceptive Advisors Portfolio holdings

AUM $6.66B
1-Year Est. Return 360.84%
This Fund
S&P 500
This Quarter Est. Return
-1.57%
1 Year Est. Return
+360.84%
3 Year Est. Return
+1,707.27%
5 Year Est. Return
+3,210.42%
10 Year Est. Return
+53,055.89%
AUM
$6.49B
AUM Growth
-$396M
Cap. Flow
-$220M
Cap. Flow %
-3.39%
Top 10 Hldgs %
43.16%
Holding
163
New
23
Increased
16
Reduced
43
Closed
16

Top Buys

Rank Stock Value
1
LIAN
LianBio American Depositary Shares
LIAN
+$643M
2
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$97.4M
3
BLU
BELLUS Health Inc.
BLU
+$50.7M
4
ISO
IsoPlexis Corporation Common Stock
ISO
+$45.4M
5
ZNTL icon
Zentalis Pharmaceuticals
ZNTL
+$33.3M

Top Sells

Rank Stock Value
1
AVIR icon
Atea Pharmaceuticals
AVIR
+$79.2M
2
NVTA
Invitae Corporation
NVTA
+$50.6M
3
BEAM icon
Beam Therapeutics
BEAM
+$46.8M
4
DBVT
DBV Technologies
DBVT
+$37.7M
5
IOVA icon
Iovance Biotherapeutics
IOVA
+$30M

Sector Composition

Rank Sector Weight
1 Healthcare 85.98%
2 Miscellaneous 13.04%
3 Financials 0.8%
4 Industrials 0.09%
5 Consumer Staples 0.06%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
INBX
26
DELISTED
Inhibrx, Inc. Common Stock
INBX
$58.7M 0.9%
1,343,490
+222,000
+20% +$8.88M
TVTX icon
27
Travere Therapeutics
TVTX
$5.89B
$57.3M 0.88%
1,845,555
-120,000
-6% -$3.38M
ALBO
28
DELISTED
Albireo Pharma Inc
ALBO
$55M 0.85%
2,360,139
– –
CCXI
29
DELISTED
ChemoCentryx, Inc.
CCXI
$51.5M 0.79%
1,415,446
+865,446
+157% +$30.4M
NAUT icon
30
Nautilus Biotechnolgy
NAUT
$113M
$47.2M 0.73%
9,111,151
+200,000
+2% +$1.07M
ARNA
31
DELISTED
Arena Pharmaceuticals Inc
ARNA
$46.5M 0.72%
+500,000
New +$32.9M
LONA
32
LeonaBio Inc
LONA
$68.2M
$44.6M 0.69%
342,592
– –
KOD icon
33
Kodiak Sciences
KOD
$2.07B
$44.1M 0.68%
520,152
+58,904
+13% +$5.99M
ICVX
34
DELISTED
Icosavax, Inc. Common Stock
ICVX
$43.6M 0.67%
1,906,548
-16,001
-0.8% -$413K
RCKT icon
35
Rocket Pharmaceuticals
RCKT
$374M
$42.8M 0.66%
1,959,125
-351,136
-15% -$9.58M
QTNT
36
DELISTED
Quotient Limited Ordinary Shares
QTNT
$42M 0.65%
405,020
– –
NBIX icon
37
Neurocrine Biosciences
NBIX
$15.2B
$41.1M 0.63%
483,007
– –
MORF
38
DELISTED
Morphic Holding, Inc. Common Stock
MORF
$39.6M 0.61%
836,521
-50,819
-6% -$2.73M
ALDX icon
39
Aldeyra Therapeutics
ALDX
$82.6M
$39.6M 0.61%
9,903,879
– –
OMIC
40
DELISTED
Singular Genomics Systems, Inc. Common Stock
OMIC
$38.5M 0.59%
111,127
+8,666
+8% +$3.36M
ISO
41
DELISTED
IsoPlexis Corporation Common Stock
ISO
$37.6M 0.58%
+4,095,498
New +$45.4M
ACAD icon
42
Acadia Pharmaceuticals
ACAD
$4.61B
$37M 0.57%
+1,584,052
New +$31.9M
ZNTL icon
43
Zentalis Pharmaceuticals
ZNTL
$296M
$36.2M 0.56%
+430,544
New +$33.3M
IMTX icon
44
Immatics
IMTX
$1.31B
$33.6M 0.52%
2,500,000
– –
PRCT icon
45
Procept Biorobotics
PRCT
$1.11B
$33.2M 0.51%
1,328,285
-328,705
-20% -$12.2M
VRCA icon
46
Verrica Pharmaceuticals
VRCA
$78.7M
$33.1M 0.51%
361,041
– –
KRON
47
DELISTED
Kronos Bio
KRON
$32.9M 0.51%
2,421,142
– –
RAIN
48
DELISTED
Rain Oncology Inc. Common Stock
RAIN
$32M 0.49%
2,483,619
-53,400
-2% -$763K
TARS icon
49
Tarsus Pharmaceuticals
TARS
$3.66B
$29.2M 0.45%
1,296,416
– –
VRDN icon
50
Viridian Therapeutics
VRDN
$2.47B
$28.1M 0.43%
1,423,053
+53
+0% +$987
1
2
3 4 5

Similar funds

QP
Quilter Plc London, United Kingdom $6.65B AUM 37.83% 1-Year Est. Return
FCBT
First Citizens Bank & Trust Raleigh, North Carolina $6.69B AUM 24.48% 1-Year Est. Return
RWM
Ritholtz Wealth Management New York $6.7B AUM 32.7% 1-Year Est. Return
AWA
Arkadios Wealth Advisors Atlanta, Georgia $6.6B AUM 30.67% 1-Year Est. Return
WHRC
W.H. Reaves & Co Jersey City, New Jersey $6.59B AUM 31.9% 1-Year Est. Return
KGA
K5 Global Advisor Miami Beach, Florida $6.59B AUM
LSERS
Louisiana State Employees Retirement System Baton Rouge, Louisiana $6.74B AUM 53.06% 1-Year Est. Return
CAG
Crestwood Advisors Group Boston, Massachusetts $6.74B AUM 30.22% 1-Year Est. Return

Perceptive Advisors's Q4 2021 Portfolio in Review

As of Q4 2021, Perceptive Advisors held 163 positions worth $6.49B, down 5.7% from $6.88B the previous quarter. Its ten largest holdings account for 43% of the portfolio.

Perceptive Advisors withdrew a net $220M in Q4 2021, closing 16 positions and reducing 43 holdings. Its most notable exit was Atea Pharmaceuticals, an estimated $79.2M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 86% of assets, down from 86% a quarter earlier, followed by Miscellaneous and Financials.

Against the trend, Perceptive Advisors opened a new position in LianBio American Depositary Shares worth $347M.

  • Perceptive Advisors's largest Q4 2021 buy was LianBio American Depositary Shares: 56,319,960 shares worth $347M.
  • Perceptive Advisors added most to Apellis Pharmaceuticals in Q4 2021, an estimated $32.9M increase.
  • Perceptive Advisors's biggest Q4 2021 reduction was Invitae Corporation, cutting an estimated $50.6M.
  • Perceptive Advisors fully exited Atea Pharmaceuticals in Q4 2021, selling an estimated $79.2M.
  • Perceptive Advisors's ten largest holdings make up 43% of its $6.49B portfolio in Q4 2021.
  • Perceptive Advisors opened 23 new positions and closed 16 in Q4 2021.
  • Perceptive Advisors's portfolio value fell 5.7% quarter-over-quarter to $6.49B.

Based on Perceptive Advisors's 13F filing for Q4 2021, filed 14 Feb 2022.